A recent Morbidity and Mortality Weekly Report (MMWR) highlights the risks associated with use of over-the-counter (OTC) products containing undeclared prescription ingredients as well as the importance of collaboration between various health departments and systems to ensure a prompt response to an outbreak.
Researchers developed a clinical tool to identify patients at risk for persistent abnormal glucose levels during hospitalization.
Golimumab was found to preserve β-cell function and reduce the need for exogenous insulin in young patients with type 1 diabetes.
The FDA has accepted for review the New Drug Application for dasiglucagon HypoPal® Rescue Pen (Zealand Pharma) for the treatment of severe hypoglycemia.
Several nonglycemic factors may increase the risk for the development of diabetic peripheral neuropathy (DPN) among people with type 1 diabetes.
The FDA has granted Orphan Drug designation to ABG-023, a glucagon analog (AmideBio), for the treatment of congenital hyperinsulinism.
The submission is supported by three phase 3 trials in adult and pediatric patients that showed dasiglucagon met the primary and all key secondary end points.
Fresenius Kabi announced the launch of Glucagon Emergency Kit for the treatment of severe hypoglycemic episodes in adult and pediatric patients with diabetes.
Both recent severe hypoglycemia (SH) and lifetime SH are associated with worse cognition among older adults with type 1 diabetes.
Intermittently scanned continuous glucose monitoring results in higher treatment satisfaction among adults with type 1 diabetes.
